AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back
阿斯利康的obesity pill在II期试验中达到主要终点，关键肿瘤试验被推迟

The biopharma sector is in the grip of obesity pill mania, and AstraZeneca added to that on Tuesday by revealing that its oral GLP-1 elecoglipron had hit in two mid-stage trials – one in obesity and another in diabetes. The pill is about to enter Phase 3 testing.
生物制药行业正陷入obesity pill狂热。阿斯利康周二披露，其口服GLP-1药物elecoglipron在两项中期试验中达到了主要终点：一项针对肥胖，另一项针对糖尿病。该药片即将进入三期临床试验。